Zilurgisertib

DB18152ApprovedInvestigationalSmall molecule

Zilurgisertib is an oral activin receptor-like kinase-2 (ALK2) inhibitor indicated to reduce the volume of total new heterotopic ossification in adults and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva. It inhibits both wild-type ALK2 and the pathogenic R206H mutant form.

Chemical structure of Zilurgisertib
Mechanism
Curator reviewed · 4 references
Primary indication
Zilurgisertib is indicated to reduce the volume of total new heterotopic ossification (HO) in adults and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP).Curator reviewed · 1 structured indication
Formula / weight
C30H38N4O3 · 502.659 g/mol (avg)
First approval
United States, 2026
Code names
INCB-000928 · NBU-928 free base

Resolves to

Clinical / RWD
Structure
InChIKeyKPRPFTOLWQQUAV-OCVAFRRMSA-NSMILESNC1=NC=C(C=C1C(=O)NC12CCC(O)(CC1)CC2)C1=CC=C(C=C1)[C@@]12C[C@@H]1CN(C2)C1CCOCC1

What you can answer from here — as of October 28, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
8TransportersSubstrate / inhibitor direction, not just membership
Listed above
82Drug interactionsStructured to mechanism, not free text
Sign in
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
1Marketed productAcross 1 country and 1 labeller
Sign in
17+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Zilurgisertib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account